Patient and treatment characteristics
| Patient characteristics . | No. . |
|---|---|
| Age, median, y (range) | 7.4 (0.2-56.9) |
| Weight, median, kg (range) | 25.9 (5.0-107.5) |
| Sex, no. (%) | |
| Male | 60 (59) |
| Female | 42 (41) |
| Race, no. (%) | |
| White | 80 (78) |
| Other | 22 (22) |
| CMV serostatus, no. (%) | |
| Negative | 61 (60) |
| Positive | 41 (40) |
| Diagnosis, no. (%) | |
| Malignant disease | |
| Acute lymphocytic leukemia | 28* (27) |
| Acute myelocytic leukemia | 26† (25) |
| Chronic myelogenous leukemia | 6‡ (6) |
| Juvenile myelomonocytic leukemia | 3 (3) |
| Non-Hodgkin lymphoma | 1 (1) |
| Hodgkin disease | 1 (1) |
| Nonmalignant disease | |
| Severe aplastic anemia | 2 (2) |
| Fanconi anemia | 4 (4) |
| Diamond-Blackfan syndrome | 1 (1) |
| Osteopetrosis | 1 (1) |
| Myelodysplastic syndrome (refractory anemia) | 3 (3) |
| Immune deficiency | 5 (5) |
| Metabolic disorders | 21 (21) |
| Degree of HLA-A, B, DRB1 match, no. (%)1-153 | |
| 6/6 antigens | 14 (14) |
| 5/6 antigens | 44 (43) |
| 4/6 antigens | 42 (41) |
| 3/6 antigens | 2 (2) |
| ABO blood type match, no. (%) | |
| Match | 32 (31) |
| Minor mismatch | 36 (35) |
| Major mismatch | 34 (33) |
| Treatment, no. (%) | |
| TBI | 87 (85) |
| No TBI | 15 (15) |
| G-CSF | 80 (78) |
| No G-CSF | 22 (22) |
| Patient characteristics . | No. . |
|---|---|
| Age, median, y (range) | 7.4 (0.2-56.9) |
| Weight, median, kg (range) | 25.9 (5.0-107.5) |
| Sex, no. (%) | |
| Male | 60 (59) |
| Female | 42 (41) |
| Race, no. (%) | |
| White | 80 (78) |
| Other | 22 (22) |
| CMV serostatus, no. (%) | |
| Negative | 61 (60) |
| Positive | 41 (40) |
| Diagnosis, no. (%) | |
| Malignant disease | |
| Acute lymphocytic leukemia | 28* (27) |
| Acute myelocytic leukemia | 26† (25) |
| Chronic myelogenous leukemia | 6‡ (6) |
| Juvenile myelomonocytic leukemia | 3 (3) |
| Non-Hodgkin lymphoma | 1 (1) |
| Hodgkin disease | 1 (1) |
| Nonmalignant disease | |
| Severe aplastic anemia | 2 (2) |
| Fanconi anemia | 4 (4) |
| Diamond-Blackfan syndrome | 1 (1) |
| Osteopetrosis | 1 (1) |
| Myelodysplastic syndrome (refractory anemia) | 3 (3) |
| Immune deficiency | 5 (5) |
| Metabolic disorders | 21 (21) |
| Degree of HLA-A, B, DRB1 match, no. (%)1-153 | |
| 6/6 antigens | 14 (14) |
| 5/6 antigens | 44 (43) |
| 4/6 antigens | 42 (41) |
| 3/6 antigens | 2 (2) |
| ABO blood type match, no. (%) | |
| Match | 32 (31) |
| Minor mismatch | 36 (35) |
| Major mismatch | 34 (33) |
| Treatment, no. (%) | |
| TBI | 87 (85) |
| No TBI | 15 (15) |
| G-CSF | 80 (78) |
| No G-CSF | 22 (22) |
TBI indicates total body irradiation; G-CSF, prophylactic granulocyte colony-stimulating factor.
Of these patients, 8 had complete remission (CR) 1, 10 had CR 2, 6 had CR 3 or higher, and 4 had early relapse.
Of these patients, 1 had CR 1, 14 had CR 2, 1 had CR 3 or higher, and 10 had relapse.
Of these patients, 3 had chronic phase and 3 had accelerated phase disease.
Maximal degree of HLA disparity (rejection/GVHD vector).